Hologic (Nasdaq:HOLX) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

HOLX Overzicht aandelen

HOLX fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	1/6
Prestaties in het verleden	5/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 47% onder onze schatting van de reële waarde

De winst zal naar verwachting met 10.68% per jaar groeien

De winst groeide het afgelopen jaar met 43.2%

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

HOLX onze risicocontroles hebben doorstaan.

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Panther System Expansion And Critical Acquisitions Poised To Drive Growth In Molecular Diagnostics

US$86.93

7.7% undervalued

5.51%

Revenue growth p.a.

4 days ago

Hologic, Inc. Concurrenten

Zimmer Biomet Holdings

NYSE:ZBH

US$21.3b

STERIS

NYSE:STE

US$22.8b

Teleflex

NYSE:TFX

US$11.3b

Insulet

NasdaqGS:PODD

US$16.1b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Hologic
Historische aandelenkoersen
Huidige aandelenkoers	US$80.24
52 Week Hoogtepunt	US$84.67
52 Week Laag	US$64.02
Bèta	0.98
11 maand verandering	-1.63%
3 maanden verandering	7.66%
1 Jaar Verandering	14.89%
33 jaar verandering	12.43%
5 jaar verandering	64.46%
Verandering sinds IPO	3,256.44%

Recent nieuws en updates

Recent updates

Hologic (NASDAQ:HOLX) Has More To Do To Multiply In Value Going Forward

Sep 16

Hologic, Inc. (NASDAQ:HOLX) Not Flying Under The Radar

Sep 01

Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them

Aug 27

Is There Now An Opportunity In Hologic, Inc. (NASDAQ:HOLX)?

Jul 21

These 4 Measures Indicate That Hologic (NASDAQ:HOLX) Is Using Debt Reasonably Well

Jun 20

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

May 22

Hologic: Women's Health Play Looks Healthier Itself

May 13

Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult

Apr 19

Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)

Apr 05

Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet

Mar 20

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Feb 22

Hologic: Prospects For Growth As Headwinds Disappear

Feb 11

We Think You Can Look Beyond Hologic's (NASDAQ:HOLX) Lackluster Earnings

Feb 09

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

Feb 06

We Like These Underlying Return On Capital Trends At Hologic (NASDAQ:HOLX)

Jan 29

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

Dec 30

Are Investors Undervaluing Hologic, Inc. (NASDAQ:HOLX) By 25%?

Dec 11

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Nov 08

Should You Think About Buying Hologic, Inc. (NASDAQ:HOLX) Now?

Oct 25

Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement

Sep 28

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 35% Above Its Share Price

Aug 29

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Jul 31

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Jul 18

Return Trends At Hologic (NASDAQ:HOLX) Aren't Appealing

Jun 21

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

May 22

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Apr 25

What Does Hologic, Inc.'s (NASDAQ:HOLX) Share Price Indicate?

Apr 10

Hologic's (NASDAQ:HOLX) Returns On Capital Are Heading Higher

Mar 13

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

Feb 14

Hologic (NASDAQ:HOLX) Seems To Use Debt Quite Sensibly

Jan 18

Is Now The Time To Look At Buying Hologic, Inc. (NASDAQ:HOLX)?

Jan 03

Rendement voor aandeelhouders

	HOLX	US Medical Equipment	US Markt
7D	-0.7%	-1.1%	0.4%
1Y	14.9%	20.8%	32.6%

Rendement versus industrie: HOLX presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van 22.6 % opleverde.

Rendement versus markt: HOLX presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 34.1 % opleverde.

Prijsvolatiliteit

Is HOLX's price volatile compared to industry and market?
HOLX volatility
HOLX Average Weekly Movement	2.5%
Medical Equipment Industry Average Movement	8.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: HOLX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 2% ) van HOLX is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1985	6,990	Steve MacMillan	www.hologic.com

Hologic, Inc. ontwikkelt, produceert en levert diagnostische producten, medische beeldvormingssystemen en chirurgische producten voor de gezondheid van vrouwen door vroegtijdige opsporing en behandeling. Het bedrijf is actief in vier segmenten: Diagnostics, Breast Health, GYN Surgical en Skeletal Health. Het bedrijf levert Aptima moleculair diagnostische assays om infectieuze micro-organismen op te sporen; Aptima viral load assays voor hepatitis B-virus, hepatitis C-virus, humaan immunodeficiëntievirus en humaan cytomegalovirus; Aptima bacteriële vaginose en candida vaginitis assays voor de diagnose van vaginitis; Aptima SARS-CoV-2 en Panther Fusion SARS-CoV-2 assays voor de detectie van SARS-CoV-2; ThinPrep System voor cytologische toepassingen; en Rapid Fetal Fibronectin Test die artsen helpt bij het beoordelen van het risico op vroeggeboorte.

Hologic, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Hologic zich tot de beurswaarde?
HOLX fundamentele statistieken
Marktkapitalisatie	US$18.64b
Inkomsten(TTM)	US$701.50m
Inkomsten(TTM)	US$3.99b

26.6x

Koers/Winstverhouding

4.7x

P/S-verhouding

Is HOLX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
HOLX resultatenrekening (TTM)
Inkomsten	US$3.99b
Kosten van inkomsten	US$1.57b
Brutowinst	US$2.42b
Overige uitgaven	US$1.71b
Inkomsten	US$701.50m

Laatst gerapporteerde inkomsten

Jun 29, 2024

Volgende inkomensdatum

Nov 04, 2024

Winst per aandeel (EPS)	3.02
Brutomarge	60.58%
Nettowinstmarge	17.59%
Schuld/Eigen Vermogen Verhouding	51.4%

Hoe presteerde HOLX op de lange termijn?

Bekijk historische prestaties en vergelijking

HOLX Overzicht aandelen

Beloningen

Risicoanalyse

Panther System Expansion And Critical Acquisitions Poised To Drive Growth In Molecular Diagnostics

Hologic, Inc. Concurrenten

NYSE:ZBH

US$21.3b

NYSE:STE

US$22.8b

NYSE:TFX

US$11.3b

NasdaqGS:PODD

US$16.1b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Hologic, Inc. to Report Q4, 2024 Results on Nov 04, 2024

Hologic (NASDAQ:HOLX) Has More To Do To Multiply In Value Going Forward

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $1,500 million worth of its shares.

Hologic, Inc. (NASDAQ:HOLX) Not Flying Under The Radar

Chief Financial Officer notifies of intention to sell stock

Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them

Recent updates

Hologic, Inc. to Report Q4, 2024 Results on Nov 04, 2024

Hologic (NASDAQ:HOLX) Has More To Do To Multiply In Value Going Forward

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $1,500 million worth of its shares.

Hologic, Inc. (NASDAQ:HOLX) Not Flying Under The Radar

Chief Financial Officer notifies of intention to sell stock

Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them

Chairman notifies of intention to sell stock

Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Endomagnetics Ltd. for approximately $310 million.

Is There Now An Opportunity In Hologic, Inc. (NASDAQ:HOLX)?

Hologic, Inc. to Report Q3, 2024 Results on Jul 29, 2024

Now 19% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Hologic (NASDAQ:HOLX) Is Using Debt Reasonably Well

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

Hologic: Women's Health Play Looks Healthier Itself

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Reports Impairment of Intangible Assets for the Second Quarter Ended March 30, 2024

Hologic, Inc. (NasdaqGS:HOLX) signed a definitive agreement to acquire Endomagnetics Ltd. for approximately $310 million.

Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult

Now 20% undervalued

Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. to Report Q2, 2024 Results on May 02, 2024

Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet

Independent Director notifies of intention to sell stock

Now 20% undervalued

Hologic, Inc. and Biotheranostics, Inc. Announces Newly Published Study Results Reveal That Use of the Breast Cancer Index®? Test

Now 20% undervalued

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Hologic: Prospects For Growth As Headwinds Disappear

We Think You Can Look Beyond Hologic's (NASDAQ:HOLX) Lackluster Earnings

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024

We Like These Underlying Return On Capital Trends At Hologic (NASDAQ:HOLX)

Now 21% undervalued

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Now 21% undervalued

Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024

Hologic, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Independent Director notifies of intention to sell stock

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

Are Investors Undervaluing Hologic, Inc. (NASDAQ:HOLX) By 25%?

Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer

Chairman exercised options and sold US$2.1m worth of stock

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024

Full year 2023 earnings: EPS misses analyst expectations

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $500 million worth of its shares.

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Should You Think About Buying Hologic, Inc. (NASDAQ:HOLX) Now?

Hologic, Inc. to Report Q4, 2023 Results on Nov 09, 2023

Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement

Nanaz Mohtashami Elected to Hologic, Inc.'S Board of Directors

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 35% Above Its Share Price